Spine BioPharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Spine BioPharma, Inc. - overview
Established
2015
Location
New York, NY, US
Primary Industry
Biotechnology
About
Based in New York, US, and founded in 2015, Spine BioPharma, LLC, aka Spine BioPharma operates as a provider of therapeutic solutions for spine diseases. In March 2022, Spine BioPharma, LLC raised USD 13 million in Series B funding from returning investors Cercano Management. As of 2022, the firm is led by its CEO, Marc Viscogliosi. The company’s product portfolio includes SB-01 which is a therapeutic solution for degenerative disc treatment.
The firm's solution has clinical advantages such as pain alleviation, function restoration, and disease progression avoidance. The firm plans to use the March 2022 funding for business expansion through further development of SB-01 formerly referred to as Remedisc™.
Current Investors
Vulcan, Viscogliosi Brothers, Pacira Pharmaceuticals, Inc.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Chiropractic, Orthopedic & Physical Therapy
Website
www.spinebiopharma.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.